Data_Sheet_1_Effect of saffron supplementation on oxidative stress markers (MDA, TAC, TOS, GPx, SOD, and pro-oxidant/antioxidant balance): An updated systematic review and meta-analysis of randomized placebo-controlled trials.pdf

IntroductionThis study aimed to perform an updated systematic review and meta-analysis to evaluate the effectiveness of saffron supplementation on oxidative stress markers [malondialdehyde (MDA), total antioxidant capacity (TAC), total oxidant status (TOS), glutathione peroxidase (GPx), superoxide dismutase (SOD), and prooxidant/antioxidant balance (PAB)] in randomized controlled trials (RCTs).MethodsWe searched PubMed/Medline, Web of Science, Scopus, Cochrane CENTRAL, and Google Scholar until December 2022. Trial studies investigating the effects of oral saffron supplements on MDA, TAC, TOS, GPx, SOD, and PAB concentrations were included in the study. To analyze the results, mean differences (SMD) and 95% confidence intervals (CI) were pooled using a random effects model. Heterogeneity was assessed using the Cochrane Q and I2 values. Sixteen cases were included in the meta-analysis (468 and 466 subjects in the saffron and control groups, respectively).ResultsIt was found that saffron consumption caused a significant decrease in MDA (SMD: −0.322; 95% CI: −0.53, −0.16; I2 = 32.58%) and TOS (SMD: −0.654; 95% CI: −1.08, −0.23; I2 = 68%) levels as well as a significant increase in TAC (SMD: 0.302; 95% CI: 0.13, 0.47; I2 = 10.12%) and GPx (SMD: 0.447; 95% CI: 0.10, 0.80; I2 = 35%). Subgroup analysis demonstrated a significant reduction in MDA levels in studies with a saffron dosage of >30 mg/day, age of

本研究旨在通过更新后的系统评价与荟萃分析，评估藏红花补充剂对氧化应激指标[丙二醛(MDA)、总抗氧化能力(TAC)、总氧化状态(TOS)、谷胱甘肽过氧化物酶(GPx)、超氧化物歧化酶(SOD)和氧化剂/抗氧化剂平衡(PAB)]在随机对照试验(RCTs)中的有效性。研究方法：截至2022年12月，我们检索了PubMed/Medline、Web of Science、Scopus、Cochrane CENTRAL和Google Scholar数据库。纳入了研究口服藏红花补充剂对MDA、TAC、TOS、GPx、SOD和PAB浓度影响的研究。为了分析结果，使用随机效应模型对平均差异(SMD)和95%置信区间(CI)进行了汇总。异质性评估采用Cochrane Q值和I2值。荟萃分析中包括16项研究（藏红花组466名受试者，对照组468名受试者）。结果：研究发现，藏红花摄入导致MDA（SMD：-0.322；95% CI：-0.53, -0.16；I2 = 32.58%）和TOS（SMD：-0.654；95% CI：-1.08, -0.23；I2 = 68%）水平显著降低，同时TAC（SMD：0.302；95% CI：0.13, 0.47；I2 = 10.12%）和GPx（SMD：0.447；95% CI：0.10, 0.80；I2 = 35%）水平显著升高。亚组分析显示，在藏红花剂量大于30 mg/天的研究中，MDA水平显著降低。